Status:
COMPLETED
Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Conditions:
Solid Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to learn more about how a new study agent works inside the body. This study agent is a protein called 68Ga-F(ab')2-trastuzumab fragments (HERScan). This is a radioactive t...
Eligibility Criteria
Inclusion
- Registered patient at MSKCC
- Age ≥ or = to 18 years
- Patients with invasive solid tumors.
- Measurable or evaluable disease
- Patients must have had routine disease staging studies with CT scan, FDG PET/CT scan, bone scan and/or MRI within 8 weeks of enrollment onto this trial
- Karnofsky Performance Score ≥ or = to 60
- Signed informed consent
Exclusion
- Claustrophobia/pain or any other disability leading to inability to lie still for the duration of the scanning procedure.
- Pregnancy Test to be performed on female patients of childbearing potential within 24hrs before administration of radioactive material.
- Patients with known sensitivity or contraindication to Herceptin.
- Inability to provide written informed consent.
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT00613847
Start Date
October 1 2006
End Date
December 1 2013
Last Update
October 26 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065